AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01879267 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise training
Description: 6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
Study NCT00695019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-alpha lozenges
Description: 500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
Study NCT00695019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo lozenges
Description: 200 mg matching placebo lozenges
Study NCT01031082 — intervention group
Intervention type: PROCEDURE
Intervention: Middle ear fluid, nasopharyngeal aspirate and urine sample.
Description: Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
Study NCT03858322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
Study NCT03858322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
Study NCT03858322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
Study NCT01542281 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein and dietary supplements
Description: Whey protein and dietary supplements in addition to pre-hab exercise
Study NCT01542281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prehab exercise
Description: minimum 4 weeks and maximum 8 weeks; 3 times a week
Study NCT02991079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Smartphone with APP (EVIDENT) for 3 months, cardio-health rides and feeding workshop.~Counseling on physical activity and Mediterranean diet.
Study NCT02991079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Lifestyle counseling
Description: Conseling on physical activity and nutrition (intervention)
Study NCT02991079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control: Lifestyle counseling
Description: Conseling on physical activity and nutrition (intervention)
Study NCT03100877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study NCT03100877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03652896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anatomical liver resection
Description: Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.
Study NCT00623675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineralox C
Description: Mineralox C 2 capsules three times a day.
Study NCT00314145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax™-JE
Description: 0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
Study NCT00314145 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE-VAX®
Description: 0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
Study NCT03100877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV
Study NCT01794468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermal blood flow measurements
Description: Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
Study NCT04140110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive BP lowering
Description: The aim is to achieve a systolic BP level of \<120mmHg within 1 hour after randomisation and to maintain this BP level for the next 72 hours (or until hospital discharge or death if this should occur earlier).
Study NCT01997658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients in Methylprednisolone arm will receive injection methylprednisolone 500 mg I/V over 15 to 20 minutes, single dose, 30 minutes before starting surgery.
Study NCT01997658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
Study NCT01641536 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HB-110
Description: Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
Study NCT01612195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal fistula plug
Description: All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
Study NCT02713672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose adjustment according to genotype
Description: Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
Study NCT06048224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS628+MTX
Description: Participants will receive HS628 SC injections Q4W along with MTX orally for 24-week
Study NCT06048224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actemra +MTX
Description: Participants will receive tocilizumab SC injections Q4W along with MTX orally for 24-week
Study NCT00922584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib (Nexavar)
Description: oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
Study NCT00888836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery: Gastric bypass
Description: Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
Study NCT00888836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery: Bilio-pancreatic diversion
Description: Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
Study NCT00888836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: anti-diabetic drugs and behavioral suggestions
Description: Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (\<30% total fat and \<10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
Study NCT01767337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLUGEN 101.2 device
Study NCT03100877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03100877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01563783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Global Fibroid Ablation (GFA)
Description: GFA is being used for the treatment of symptomatic uterine fibroids
Study NCT01563783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal or Laparoscopic Myomectomy
Description: Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.
Study NCT01563783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Artery Embolization (UAE)
Description: UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
Study NCT00216372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide (microparticle formulation)
Description: A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
Study NCT00216372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single intra-muscular injection on day 0.
Study NCT01555593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioline Exp'air by Medi-soft - Sorinnes (B)
Description: FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
Study NCT03617887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus.~The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region in the control group, and a specific work of gluteus medius, added to the previous one, in the experimental group.
Study NCT03617887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Plank exercise, Lateral plank exercise and Bird dog exercise. The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region.
Study NCT01867255 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: venlafaxine ER (extended-release) 75 mg
Description: A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
Study NCT03448198 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total knee replacement
Description: Primary knee gonarthrosis treated with navigated total knee replacement and computer-assisted patellar replacement.
Study NCT00519350 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection
Description: In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
Study NCT03789877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participate in home-based walking program
Study NCT03789877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Participate in home-based walking program
Study NCT03789877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03789877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03789877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Undergo rTMS
Study NCT03789877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham rTMS
Study NCT02525068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Until confirmed disease progression.
Study NCT02525068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD5363
Description: Until confirmed disease progression.
Study NCT02525068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Until confirmed disease progression.
Study NCT02525068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enzalutamide
Description: Until confirmed disease progression.
Study NCT04642222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APOLO-Teens web-based intervention
Description: The APOLO-Teens web-based intervention is a 6-month cognitive-behavioral lifestyle program developed to optimize treatment as usual for pediatric obesity in public portuguese hospitals.
Study NCT04642222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual for Pediatric Obesity
Description: Treatment as Usual for pediatric obesity in portuguese public hospitals.
Study NCT01366716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash CM
Description: Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
Study NCT01366716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher CM
Description: Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
Study NCT01217346 — intervention group
Intervention type: OTHER
Intervention: no intervention is involved in this study
Description: no intervention is involved in this study
Study NCT04222049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibro Tactile Gadget
Description: The concept is to apply vibro tactile gadget to different nerve points which when applied transmit waves to the focused parts of brain which will result in blood flow and activation of dead cells. As a result some disabled part of the body because of those dead cells can show improvement.
Study NCT02673749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-G28
Description: Study drug taken orally
Study NCT02673749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally
Study NCT03122106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen DNA vaccine
Description: -Personalized polyepitope inserts integrating the prioritized neoantigens and mesothelin epitopes will be designed and then synthesized and cloned into the pING parent vector
Study NCT03122106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM Electrode Array System
Description: -Ichor Medical Systems
Study NCT03122106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draws
Description: -Enrollment, mid adjuvant chemotherapy, end of chemotherapy, week 1, week 5, week 9, week 13, week 17, week 21, week 25, and week 77
Study NCT02707497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
Study NCT02707497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will not use any platelet-increased drugs.
Study NCT03039075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin SR Tablet
Description: Metformin SR Tablet made in Conquer pharmaceutical co., LTD
Study NCT03100877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pheresis
Description: Undergo apheresis
Study NCT03100877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT03100877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Given IV
Study NCT03100877 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Undergo TMI
Study NCT01457794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: School meals based on the principles of the New Nordic Diet
Description: The study participants are provided with three daily school meals for 3 month
Study NCT01867775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine 15 mg, at night, once a day for 14 days
Study NCT04627636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial trigger points pressure (MTrP) release
Description: Myofascial trigger points pressure (MTrP) release technique, the initial step was to recognize and find the trigger points (TP) , and The second step after TP palpation was the MTrP release technique, as follow, by one or both hands, the thumbs or four fingers of the therapist applied a maintained pressure, pushing internal toward the middle
Study NCT04627636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shockwave therapy application
Description: The JEST-2000 (JOEUN Medical, Dae-Jeon, South Korea) was used for the ESWT. The application of pressure pulses of ESWT was centered around the flexor muscles with hypertonia
Study NCT04627636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: Passive ROM exercises performed by the therapist and Bobath Neurodevelopmental Approach (prolonged stretch): The Intervention methods for Bobath involved the activation of key points of control for the reduction of tone
Study NCT02025608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Study NCT02025608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02346864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three-stair-position
Description: Infants in the TSP group received three-stair-prone position. Implementation steps were as following: 1) produced pad of three-stair-prone position the total height of which should be the same height as the head elevated 15 °. 2) Placed the infants on the pad with head on the highest ladder, chest on the second step and leg on the third step, bending the knees to the chest
Study NCT02346864 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Head elevated tilt position group
Description: Infants in the HETP group were allowed head up 15 ° prone position using a protractor with head to one side, arms against the sides of the body naturally bending, knees bent to the chest.
Study NCT02457091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
Study NCT00591539 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid Ultrasound
Description: Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
Study NCT00703209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Decompression
Description: Nerve decompression on a randomized leg, with similar skin incisions on the opposite leg so that the patient is blinded to which leg received the decompression.
Study NCT02668549 — intervention group
Intervention type: OTHER
Intervention: DB review for Doctor/Pharmacy Shopping Behavior
Description: Database review to evaluate of doctor/pharmacy shopping behaviors
Study NCT01973244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.~Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation.